Kodiak Sciences Inc. (KOD)
| Bid | 4.3 |
| Market Cap | 239.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -176.21M |
| EPS (ttm) | -3.35 |
| PE Ratio (ttm) | -1.35 |
| Forward PE | -1.25 |
| Analyst | Hold |
| Ask | 4.64 |
| Volume | 351,174 |
| Avg. Volume (20D) | 385,147 |
| Open | 4.40 |
| Previous Close | 4.36 |
| Day's Range | 4.15 - 4.70 |
| 52-Week Range | 1.92 - 11.60 |
| Beta | 2.40 |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, a...
Analyst Forecast
According to 3 analyst ratings, the average rating for KOD stock is "Hold." The 12-month stock price forecast is $4, which is a decrease of -11.70% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal DisordersKodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, ...